October 10, 2011 from 4:30 pm – 6:00 pm
Stanford Law School, Room 190
Last year, the United States District Court for the Southern District of New York shocked the IP world by declaring Myriad’s BRCA gene patents invalid. The striking decision in Association for Molecular Pathology v. US conflicted with practice in the United States for the past 30-odd years, which has maintained that genes and associated products and methods are patentable. In July, the Court of Appeals for the Federal Circuit reversed the district court’s decision and affirmed the validity of Myriad’s cancer screening claims. The plaintiffs challenging the validity of Myriad’s patents are now deciding between requesting an en banc hearing from the Federal Circuit, or seeking review by the Supreme Court.
On Monday, October 10, the Center for Law and the Biosciences will host a panel of experts to discuss the case, as well as its connections with two related cases, Prometheus v. Mayo, pending before the Supreme Court, and Classen v. Biogen. The panel will include Daniel Ravicher, plaintiff AMP’s attorney, and Ed Reines, a patent litigator and partner at Weil Gotshal. Professor Mark Lemley will moderate what promises to be an engaging discussion on a pressing issue of public concern.
This event is open to the public and free of charge. Please register by following this link.
